Johnson & Johnson Sample Contracts

Among
Agreement and Plan of Merger • December 20th, 2004 • Johnson & Johnson • Pharmaceutical preparations • Indiana
AutoNDA by SimpleDocs
INSTRUCTIONS
Subscription Agreement • January 27th, 1998 • Johnson & Johnson • Pharmaceutical preparations
CONFORMED COPY AGREEMENT AND PLAN OF MERGER Dated as of January 26, 2001
Agreement and Plan of Merger • February 5th, 2001 • Johnson & Johnson • Pharmaceutical preparations • Delaware
RECITALS
Stock Option Agreement • June 2nd, 1997 • Johnson & Johnson • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER by and among JOHNSON & JOHNSON, ATHOS MERGER SUB, INC. and ABIOMED, INC. Dated as of October 31, 2022
Agreement and Plan of Merger • November 1st, 2022 • Johnson & Johnson • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 31, 2022 by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Athos Merger Sub, Inc., a Delaware corporation and a direct or indirect wholly owned Subsidiary of Parent (“Merger Sub”), and ABIOMED, Inc., a Delaware corporation (the “Company”).

ARTICLE I
Johnson & Johnson • October 16th, 1997 • Pharmaceutical preparations • Delaware
AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Dated as of November 14, 2005 Among JOHNSON & JOHNSON, SHELBY MERGER SUB, INC. And GUIDANT CORPORATION
Agreement and Plan of Merger • November 18th, 2005 • Johnson & Johnson • Pharmaceutical preparations • Indiana

AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of November 14, 2005, among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), SHELBY MERGER SUB, INC., an Indiana corporation and a wholly owned Subsidiary of Parent (“Sub”), and GUIDANT CORPORATION, an Indiana corporation (the “Company”).

Contract
Registration Rights Agreement • May 8th, 2023 • Johnson & Johnson • Pharmaceutical preparations • Delaware

REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 3, 2023, between Johnson & Johnson, a New Jersey corporation (“J&J”), and Kenvue Inc., a Delaware corporation (the “Company”).

JOHNSON & JOHNSON UNDERWRITING AGREEMENT STANDARD PROVISIONS (DEBT) February 16, 2023
Underwriting Agreement • February 16th, 2023 • Johnson & Johnson • Pharmaceutical preparations

This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

AND UNITED STATES TRUST COMPANY OF NEW YORK, as Trustee
Johnson & Johnson • November 19th, 1999 • Pharmaceutical preparations • New York
AGREEMENT AND PLAN OF MERGER between JOHNSON & JOHNSON, KITE MERGER SUB, INC. and COUGAR BIOTECHNOLOGY, INC. dated as of
Agreement and Plan of Merger • May 29th, 2009 • Johnson & Johnson • Pharmaceutical preparations • Delaware

This AGREEMENT AND PLAN OF MERGER (hereinafter referred to as this “Agreement”), dated as of May 21, 2009, is by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Kite Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”), and Cougar Biotechnology, Inc., a Delaware corporation (the “Company”). All capitalized terms used in this Agreement shall have the meaning ascribed to such terms in Section 9.5 or as otherwise defined elsewhere in this Agreement unless the context clearly provides otherwise.

AGREEMENT AND PLAN OF MERGER among JOHNSON & JOHNSON SAMSON ACQUISITION CORP. and SYNTHES, INC. Dated as of April 26, 2011
Agreement and Plan of Merger • May 2nd, 2011 • Johnson & Johnson • Pharmaceutical preparations • Delaware

AGREEMENT AND PLAN OF MERGER, dated as of April 26, 2011 (this “Agreement”), among JOHNSON & JOHNSON, a New Jersey Corporation (“Parent”), SAMSON ACQUISITION CORP., a Delaware Corporation and wholly owned subsidiary of Parent (“Merger Sub”), and SYNTHES, INC., a Delaware corporation (the “Company”).

TENDER AND SUPPORT AGREEMENT
Tender and Support Agreement • May 29th, 2009 • Johnson & Johnson • Pharmaceutical preparations • Delaware
TAX MATTERS AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023
Tax Matters Agreement • May 8th, 2023 • Johnson & Johnson • Pharmaceutical preparations • Delaware

TAX MATTERS AGREEMENT dated as of May 3, 2023 (this “Agreement”) by and between JOHNSON & JOHNSON, a New Jersey corporation (“J&J”), and KENVUE INC., a Delaware corporation (“Kenvue” and together with J&J, the “Parties”).

SEPARATION AGREEMENT by and between JOHNSON & JOHNSON and KENVUE INC. Dated as of May 3, 2023
Separation Agreement • May 8th, 2023 • Johnson & Johnson • Pharmaceutical preparations • Delaware

SEPARATION AGREEMENT, dated as of May 3, 2023, by and between JOHNSON & JOHNSON, a New Jersey corporation (“J&J”), and KENVUE INC., a Delaware corporation (“Kenvue”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article I hereof.

JOHNSON & JOHNSON
Nonqualified Stock Option Award Agreement • April 28th, 2023 • Johnson & Johnson • Pharmaceutical preparations • California

WWID # Total Shares: Scheduled Vesting Date(s): the date(s) set forth in the table below (each, a “Scheduled Vesting Date”) Purchase Price Per Share:

To: Goldman, Sachs & Co. (the “Seller”)
Johnson & Johnson • June 12th, 2012 • Pharmaceutical preparations

In consideration of the Seller entering into the Cover Letter for Accelerated Share Repurchase dated as of June 12, 2012 (together with the Schedule of Standard Terms and Conditions attached thereto as Annex I, the “Agreement”) with Janssen Pharmaceutical, a company organized under the laws of Ireland and acting on its own behalf and not as an agent of any other entity (the “Company”), and in place of Seller conducting full financial diligence on the Company that would require significant lead time, Johnson & Johnson (“the undersigned”), for itself, its successors and its permitted assigns, hereby makes the following guaranty for the benefit of the Seller and its successors and permitted assigns:

Contract
Agreement and Plan of Merger • January 12th, 2006 • Johnson & Johnson • Pharmaceutical preparations • Indiana

AMENDMENT NO. 1 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER (this “Amendment”) dated as of January 11, 2006, by and among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), SHELBY MERGER SUB, INC., an Indiana corporation and a wholly owned Subsidiary of Parent (“Sub”), and GUIDANT CORPORATION, an Indiana corporation (the “Company”).

AutoNDA by SimpleDocs
Confidential Execution Copy
Shareholder Agreement • September 17th, 2010 • Johnson & Johnson • Pharmaceutical preparations
Omrix Biopharmaceuticals, Inc. 1120 Avenue of the Americas 4th Floor New York, NY 10036
Johnson & Johnson • November 25th, 2008 • Pharmaceutical preparations • Delaware

This letter agreement is in reference to the employment agreement between you and Omrix Biopharmaceuticals, Inc. (the “Company”), dated as of the 20th day of March 2006 (the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Whitewater Acquisition Corp., a wholly-owned subsidiary of Parent (“Sub”), and the Company propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in the Company becoming wholly-owned by Parent upon the Closing (as defined in the Merger Agreement) as a result of the Merger (as defined in the Merger Agreement). As a condition to the willingness of Parent and Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the Employment Agreement and any other agreement between you and the Company that provi

AMONG
Confidentiality Agreement • October 9th, 1998 • Johnson & Johnson • Pharmaceutical preparations • Delaware
Contract
Phase-Out License Agreement • May 8th, 2023 • Johnson & Johnson • Pharmaceutical preparations • Delaware

TRADEMARK PHASE-OUT LICENSE AGREEMENT dated as of April 3, 2023 (this “Agreement”), by and between JOHNSON & JOHNSON, a New Jersey corporation (“J&J”), and JOHNSON & JOHNSON CONSUMER INC. (“JJCI”). J&J and JJCI may be referred to herein individually as a “Party” and collectively as the “Parties”.

Omrix Biopharmaceuticals, Inc. 1120 Avenue of the Americas 4th Floor New York, NY 10036
Johnson & Johnson • November 25th, 2008 • Pharmaceutical preparations • Delaware

This letter agreement is in reference to the employment agreement between you and Omrix Biopharmaceuticals, Inc. (the “Company”), dated as of January 1, 2008 (the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation. (“Parent”). Whitewater Acquisition Corp., a wholly owned subsidiary of Parent (“Sub”), and the Company propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in the Company becoming wholly-owned by Parent upon the Closing (as defined in the Merger Agreement) as a result of the Merger (as defined in the Merger Agreement). As a condition to the willingness of Parent and Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the Employment Agreement and any other agreement between you and the Company that provides for se

CONTINGENT VALUE RIGHTS AGREEMENT
Contingent Value Rights Agreement • December 22nd, 2022 • Johnson & Johnson • Pharmaceutical preparations • Delaware

THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 22, 2022 (this “Agreement”), is entered into by and between Johnson & Johnson, a New Jersey corporation (“Parent”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as Rights Agent (the “Rights Agent”).

JOHNSON & JOHNSON 2022 LONG-TERM INCENTIVE PLAN GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT
Global Performance Share Unit Award Agreement • April 28th, 2023 • Johnson & Johnson • Pharmaceutical preparations • California

WWID # Target Number of PSUs: Grant Date: Performance Period: Scheduled Vesting Date: The third anniversary of the Grant Date (the “Scheduled Vesting Date”) Certification Date: The date following the end of the Performance Period on which the Committee certifies the level of achievement of the performance-based vesting criteria set forth in Appendix A hereto

Joshua Levine 201 Mentor Drive Santa Barbara, CA 93111 Re: Retention Agreement Dear Joshua:
Johnson & Johnson • December 12th, 2008 • Pharmaceutical preparations • California

This letter agreement is in reference to the employment agreement between you and Mentor Corporation (the “Company”), dated as of December 21, 2007 (the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Decatur Acquisition Corp. a wholly-owned subsidiary of Parent (“Sub”), and the Company, propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in the Company (or the surviving corporation in the merger pursuant to the Merger Agreement (the “Merger”)) becoming wholly-owned by Parent upon the Closing (as defined in the Merger Agreement). As a condition to the willingness of Parent and Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the Employment Agreement and any other agreement between you and the Company that

REGISTRATION RIGHTS AGREEMENT dated as of September 28, 2009 between CRUCELL N.V. and JHC NEDERLAND B.V.
Registration Rights Agreement • September 17th, 2010 • Johnson & Johnson • Pharmaceutical preparations • New York

REGISTRATION RIGHTS AGREEMENT, dated as of September 28, 2009 (this “Agreement”), between Crucell N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company” ), and JHC Nederland B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Investor”).

AGREEMENT AND PLAN OF MERGER Dated as of December 1, 2008 Among JOHNSON & JOHNSON, MAPLE MERGER SUB, INC. And MENTOR CORPORATION
Agreement and Plan of Merger • December 12th, 2008 • Johnson & Johnson • Pharmaceutical preparations • Minnesota

AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of December 1, 2008, among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), MAPLE MERGER SUB, INC., a Minnesota corporation and a wholly owned Subsidiary of Parent (“Sub”), and MENTOR CORPORATION, a Minnesota corporation (the “Company”).

Joseph A. Newcomb 201 Mentor Drive Santa Barbara, CA 93111 Re: Retention Agreement Dear Joseph:
Letter Agreement • December 12th, 2008 • Johnson & Johnson • Pharmaceutical preparations • California

This letter agreement is in reference to the employment agreement between you and Mentor Corporation (the “Company”), dated as of December 21, 2007 (the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Decatur Acquisition Corp. a wholly-owned subsidiary of Parent (“Sub”), and the Company, propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in the Company (or the surviving corporation in the merger pursuant to the Merger Agreement (the “Merger”)) becoming wholly-owned by Parent upon the Closing (as defined in the Merger Agreement). As a condition to the willingness of Parent and Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the Employment Agreement and any other agreement between you and the Company that

EQUITY PURCHASE AGREEMENT JHC NEDERLAND B.V. and CRUCELL N.V. Dated 28 September, 2009
Equity Purchase Agreement • September 17th, 2010 • Johnson & Johnson • Pharmaceutical preparations

or at any such other address of which it shall have given notice for this purpose to the other parties under this Clause. Any notice or other communication sent by post shall be sent by prepaid first class post or registered mail (if the country of destination is the same as the country of origin) or by pre-paid airmail (if the country of destination is not the same as the country of origin).

JOHNSON & JOHNSON GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT
Restricted Share Unit Award Agreement • April 28th, 2023 • Johnson & Johnson • Pharmaceutical preparations • California

WWID # Total Units: Grant Date: Scheduled Vesting Date(s): the date(s) set forth in the table below (each, a “Scheduled Vesting Date”)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!